Benjamin Kaffenberger
Dermatologist
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Benjamin Kaffenberger as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:23 UTC. Open this list on ClinicalTrials.gov
- N/ANCT03146676 · The Ohio State University Dermatology BiorepositoryOhio State University · recruiting · Hidradenitis Suppurativa · principal investigator
- Ph2NCT03137160 · An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma GangrenosumOhio State University · completed · Pyoderma Gangrenosum · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:23 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:23 UTC. The ranking covers the 200 most relevant of 5 PubMed records, and a shared surname and initials can bring in a namesake. All 5 on PubMed
- Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus.N Engl J Med · 2022117 citationsRCR 8.9
- Impact of dermatology and teledermatology consultations for patients admitted with cellulitis: A pilot study.J Am Acad Dermatol · 202014 citationsRCR 1.2
- A randomized phase 2 trial of the efficacy and safety of a novel topical povidone-iodine formulation for Cancer therapy-associated Paronychia.Invest New Drugs · 201910 citationsRCR 0.6
- Radiation Recall Dermatitis With Concomitant Dabrafenib and Pazopanib Therapy.JAMA Dermatol · 20169 citationsRCR 0.4
- The effect of histopathologic analysis and tissue cultures on inpatient management of cellulitis: a randomized control trial.Arch Dermatol Res · 20242 citationsRCR 0.7